Canaccord analyst Edward Nash raised the firm’s price target on Akero Therapeutics to $58 from $50 and keeps a Buy rating on the shares. The analyst said the increase is based on an adjustment in pricing to be in line with branded T2D injectables as well as an extension in the out-year of our model from 2029 to 2032.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AKRO: